Cystic fibrosis (CF) is a complex genetic disorder that affects multiple organ systems, most notably the lungs and pancreas. Over the past two decades, improvements in respiratory care have extended survival, shifting the clinical focus toward managing complications that emerge with age. One of the most significant is cystic fibrosis-related diabetes (CFRD), a distinct form of diabetes that combines features of both type 1 and type 2 diabetes. CFRD affects up to 20% of adolescents and 40–50% of adults with CF, and its onset marks a turning point in disease progression. Patients who develop CFRD experience faster decline in lung function, worse nutritional outcomes, and higher mortality rates compared to those without diabetes.

The relationship between lung health and glucose metabolism in CF is not a one-way street but a bidirectional loop. Pulmonary inflammation worsens insulin resistance, while hyperglycemia impairs immune function and promotes bacterial growth in the airways. This synergy makes isolated management of either condition ineffective. Clinicians who treat CF must adopt an integrated model of care that addresses both pulmonary and metabolic health simultaneously.

The Bidirectional Relationship Between Lung Function and Glucose Metabolism

Unique Pathophysiology of CFRD

CFRD differs fundamentally from type 1 and type 2 diabetes. The primary defect is progressive fibrosis and destruction of the pancreatic islets, which reduces insulin production capacity. However, CFRD also involves intermittent insulin resistance triggered by acute illness, systemic inflammation, and glucocorticoid therapy. The result is a delayed and blunted insulin secretory response, particularly after meals. Early in CFRD, patients maintain normal fasting glucose but exhibit marked postprandial hyperglycemia. As the disease advances, fasting hyperglycemia develops as well.

The variability of glucose tolerance in CFRD is remarkable. A patient who shows normal glucose tolerance at a routine clinic visit may develop severe hyperglycemia during a pulmonary exacerbation. This unpredictability makes static management protocols inadequate. Diabetes care in CF must be dynamic, responsive to the patient's current respiratory status, infection burden, and medication regimen.

How Lung Inflammation Drives Insulin Resistance

Chronic airway inflammation in CF is driven by persistent bacterial infection, neutrophil-dominated inflammation, and the release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β). These cytokines interfere with insulin signaling at multiple points. TNF-α promotes serine phosphorylation of insulin receptor substrate-1 (IRS-1), which inhibits downstream activation of phosphatidylinositol 3-kinase (PI3K) and reduces glucose transporter type 4 (GLUT4) translocation to the cell membrane. The net effect is diminished glucose uptake in skeletal muscle and adipose tissue.

During acute pulmonary exacerbations, systemic inflammation escalates, and cortisol levels rise further, promoting hepatic gluconeogenesis and worsening insulin resistance. Patients often require substantial increases in insulin doses during these periods. The inflammatory burden also affects the liver, increasing endogenous glucose production and contributing to fasting hyperglycemia. This explains why aggressive treatment of lung infections can produce rapid improvements in blood glucose control.

Pulmonary Exacerbations and Glycemic Instability

Pulmonary exacerbations are episodes of acute worsening of respiratory symptoms requiring antibiotic therapy and intensified airway clearance. These events are particularly disruptive to glucose metabolism. Elevated cortisol from illness-related stress increases insulin resistance, while reduced oral intake and gastrointestinal symptoms complicate nutritional management. Many patients require initiation or escalation of insulin therapy during exacerbations, even if they did not previously meet criteria for CFRD.

A study in the American Journal of Respiratory and Critical Care Medicine demonstrated that patients with CF who experienced frequent exacerbations had higher average blood glucose levels and greater glycemic variability. The same study found that poor glycemic control during an exacerbation was associated with longer recovery times and lower FEV1 at follow-up. This creates a dangerous feedback loop: worsening lung function causes hyperglycemia, which in turn impairs immune function, increasing susceptibility to further infections.

Physical Activity, Sarcopenia, and Metabolic Health

Lung function, measured by forced expiratory volume in one second (FEV1), directly determines exercise capacity. Patients with advanced lung disease often limit physical activity due to dyspnea, fatigue, and oxygen desaturation. Reduced activity leads to loss of skeletal muscle mass, known as sarcopenia, which is common in CF. Muscle tissue is the primary site of glucose disposal after meals. When muscle mass declines, the body's capacity to clear glucose from the blood diminishes, worsening insulin resistance.

Physical activity also stimulates GLUT4 expression and enhances insulin sensitivity independently of muscle mass. Regular exercise has been shown to improve glycemic control in patients with CFRD, even after accounting for changes in body composition. The challenge for clinicians is to prescribe exercise programs that are safe and sustainable given the patient's pulmonary limitations. Low-impact activities such as stationary cycling, resistance training, and water-based exercise can provide metabolic benefits without overwhelming the respiratory system.

Clinical Management Strategies for Dual Disease

Integrated Multidisciplinary Care Models

CF care has long been delivered by specialized multidisciplinary teams. The addition of endocrinology expertise to these teams is now recognized as essential. The Cystic Fibrosis Foundation recommends annual oral glucose tolerance testing starting at age 10, but real-time coordination during exacerbations is equally important. Weekly case conferences that include pulmonologists, endocrinologists, dietitians, and respiratory therapists allow for proactive insulin adjustments when steroid therapy is initiated or when infection markers rise.

Centers that have implemented integrated pulmonary-endocrine clinics report fewer emergency visits for hyperglycemia and better glycemic control without increasing hypoglycemia risk. The key is communication: the respiratory team must alert the diabetes team to changes in clinical status before blood glucose becomes severely deranged. Standardized protocols for insulin adjustment based on steroid dose and infection severity can reduce variability and improve outcomes.

Continuous Glucose Monitoring in Acute and Chronic Care

Traditional fingerstick monitoring may miss the postprandial spikes and nocturnal hyperglycemia that characterize CFRD. Continuous glucose monitoring (CGM) provides real-time data that allows clinicians to tailor insulin therapy with precision. During pulmonary exacerbations, CGM can detect early increases in glucose levels that precede full hyperglycemia, enabling early intervention. Studies published in Pediatric Pulmonology have shown that CGM use in hospitalized CF patients reduces mean blood glucose and hypoglycemia rates compared to point-of-care testing alone.

For outpatient management, CGM helps identify patterns related to meal timing, exercise, and sleep. Patients can see how specific foods or activity levels affect their glucose, empowering them to make adjustments. However, CGM must be combined with aggressive pulmonary care to break the inflammation-hyperglycemia loop. Inhaled antibiotics, mucolytics, and airway clearance remain foundational, and their optimization should accompany any diabetes management plan.

Nutritional Strategies for Dual Goals

Patients with CF require high-calorie diets to maintain weight and lung function, yet many calorie-dense foods also raise blood glucose. Balancing these competing needs requires careful planning and expert guidance. Modern dietary strategies include:

  • Timed carbohydrate distribution: Spreading carbohydrate intake across smaller, more frequent meals reduces postprandial glucose spikes. Matching insulin boluses to the carbohydrate content of each meal using insulin-to-carbohydrate ratios improves glycemic control.
  • Fat and protein enrichment: Adding healthy fats and protein to meals slows gastric emptying and attenuates glucose absorption. This approach allows patients to meet calorie goals without extreme post-meal hyperglycemia.
  • Pancreatic enzyme replacement therapy (PERT) optimization: Inadequate enzyme dosing leads to maldigestion of carbohydrates, producing erratic glucose absorption and unpredictable blood sugar levels. Ensuring proper PERT dosing is a critical first step in glucose management.
  • Specialized nutritional supplements: Some CF-specific formulas are designed with lower glycemic index ingredients and added anti-inflammatory compounds such as omega-3 fatty acids. These products can help meet nutritional needs while minimizing glucose excursions.

During acute exacerbations, catabolism accelerates and insulin requirements rise. The dietitian must adjust calorie and carbohydrate goals to match the patient's changing metabolic state. Frequent reassessment is essential to prevent both hyperglycemia and weight loss.

Exercise Prescription Based on Lung Function

Exercise remains one of the most effective interventions for improving insulin sensitivity in CF. The challenge is to design programs that are safe for patients with compromised pulmonary function. Key principles include:

  • Individualization based on FEV1 and oxygen saturation: Patients with FEV1 above 60% predicted can generally tolerate moderate-intensity aerobic exercise. Those with FEV1 between 40% and 60% may benefit from interval training with rest periods. Patients with FEV1 below 40% should focus on low-intensity activities and upper body strengthening.
  • Combination with airway clearance: Pulmonary rehabilitation programs that combine supervised exercise with airway clearance techniques have been shown to improve both FEV1 and glycemic control. Exercise can enhance mucus clearance by increasing airflow and mobilizing secretions.
  • Monitoring during activity: Blood glucose should be checked before and after exercise. Patients using insulin may require dose reductions to prevent hypoglycemia during or after activity.

Even patients with advanced lung disease can benefit from short periods of activity. Five to ten minutes of gentle cycling or resistance exercises repeated throughout the day can provide metabolic benefits without causing oxygen desaturation or excessive dyspnea.

Emerging Therapies and Future Directions

CFTR Modulator Therapy and Metabolic Outcomes

The introduction of CFTR modulator drugs has transformed CF care. Ivacaftor, lumacaftor, tezacaftor, and elexacaftor correct the underlying protein defect in patients with specific CFTR mutations. Early evidence suggests that these therapies may improve pancreatic endocrine function in some patients. A study in The New England Journal of Medicine found that patients taking elexacaftor/tezacaftor/ivacaftor had slower progression to CFRD and improved glucose tolerance over a two-year period. By reducing lung inflammation and mucus burden, modulators also lower systemic cytokine levels, indirectly reducing insulin resistance.

These findings raise the possibility that early institution of modulator therapy could delay or prevent the development of CFRD. However, not all patients respond equally, and the long-term effects on beta-cell function remain under investigation. Modulators do not eliminate the need for diabetes management, but they may reduce its severity and simplify treatment.

Anti-Inflammatory Therapies Targeting the Lung-Endocrine Axis

Given the central role of inflammation in driving insulin resistance in CF, anti-inflammatory therapies represent a promising avenue for dual benefit. Several strategies are under investigation:

  • Hydroxychloroquine: An immunomodulator used in autoimmune diseases, hydroxychloroquine has shown early promise in reducing insulin resistance in CF patients with chronic Pseudomonas infection. Small studies suggest improvements in both glycemic control and lung function.
  • IL-1β inhibitors: Biologics such as anakinra target interleukin-1β, a key cytokine in the inflammatory cascade. Early-phase trials are examining whether reducing IL-1β activity can break the cycle of inflammation and hyperglycemia.
  • Glucocorticoid-sparing strategies: Reducing reliance on systemic steroids for pulmonary exacerbations could prevent steroid-induced hyperglycemia. Non-steroidal alternatives and targeted antibiotics are being evaluated.

While these approaches are experimental, they represent a shift toward treating the underlying drivers of CFRD rather than managing its metabolic consequences alone.

Artificial Pancreas Systems for CFRD

Closed-loop insulin delivery systems, often called artificial pancreas technology, have been developed primarily for type 1 diabetes. These systems combine CGM with insulin pump algorithms that adjust basal and bolus doses automatically. CFRD presents unique challenges for these algorithms due to the high variability in insulin needs driven by changing inflammation, infection, and steroid use.

A proof-of-concept study demonstrated that a hybrid closed-loop system could maintain glucose in target range during a pulmonary exacerbation better than standard insulin therapy. However, current algorithms require manual adjustment for steroid doses and may not respond quickly enough to rapid changes in insulin sensitivity. Ongoing research aims to refine these systems to account for the specific dynamics of CFRD.

Practical Recommendations for Clinicians and Patients

Healthcare providers managing patients with CF should integrate diabetes screening and management into every encounter. A practical checklist includes:

  • Review lung function trends at each diabetes visit, noting changes in FEV1 and exacerbation frequency.
  • Check point-of-care glucose at every pulmonary clinic visit, especially for patients not yet diagnosed with CFRD.
  • Preemptively adjust insulin when systemic steroids are initiated or when infection markers rise.
  • Coordinate care between pulmonary and endocrine teams, ideally through shared protocols and regular communication.

For patients and families, education about the bidirectional link between lung health and blood glucose is essential. Key self-management strategies include:

  • Track respiratory symptoms such as cough, sputum changes, and fatigue, and recognize them as triggers for more frequent glucose monitoring.
  • Maintain adherence to CFTR modulators and airway clearance routines, as these support both lung function and metabolic control.
  • Consult with a dietitian who understands CF nutrition to develop a meal plan that meets calorie needs while managing glucose.
  • Engage in regular physical activity within pulmonary limits, and monitor glucose around exercise to prevent hypoglycemia.

Conclusion

The impact of lung health on diabetes management in cystic fibrosis is both profound and reciprocal. Optimal glycemic control cannot be achieved without stable pulmonary function, and preserving lung function requires meticulous diabetes care. By integrating pulmonary and endocrine expertise, employing advanced monitoring technologies, and leveraging new therapies such as CFTR modulators, clinicians can help patients with CFRD live longer, healthier lives. The future of CF care lies in breaking down silos between specialties and recognizing that every exacerbation is both a respiratory and a metabolic event. A unified approach, proactive monitoring, and patient education are the cornerstones of improved outcomes in this challenging but increasingly manageable condition.

External resources: